Evidence map›Paper›PMID 35743555›Full record

ReviewJournal of clinical medicine2022

Application Progress of High-Throughput Sequencing in Ocular Diseases.

Xuejun He, Ningzhi Zhang, Wenye Cao, Yiqiao Xing, Ning Yang

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Emerging contaminants: A One Health perspective.Innovation (Cambridge (Mass.)) · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xuejun HeEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.
Ningzhi ZhangEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.
Wenye CaoEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.ORCID 0000-0003-1781-0555
Yiqiao XingEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.ORCID 0000-0001-5534-1951
Ning YangEye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.ORCID 0000-0003-3036-0202
Wuhan University · CN

Funding

Hubei Key Laboratories Opening Project 2021KFY055Natural Science Foundation of Hubei Province 2020CFB240
6 · The paper itself

Abstract

Ocular diseases affect multiple eye parts and can be caused by pathogenic infections, complications of systemic diseases, genetics, environment, and old age. Understanding the etiology and pathogenesis of eye diseases and improving their diagnosis and treatment are critical for preventing any adverse consequences of these diseases. Recently, the advancement of high-throughput sequencing (HTS) technology has paved wide prospects for identifying the pathogenesis, signaling pathways, and biomarkers involved in eye diseases. Due to the advantages of HTS in nucleic acid sequence recognition, HTS has not only identified several normal ocular surface microorganisms but has also discovered many pathogenic bacteria, fungi, parasites, and viruses associated with eye diseases, including rare pathogens that were previously difficult to identify. At present, HTS can directly sequence RNA, which will promote research on the occurrence, development, and underlying mechanism of eye diseases. Although HTS has certain limitations, including low effectiveness, contamination, and high cost, it is still superior to traditional diagnostic methods for its efficient and comprehensive diagnosis of ocular diseases. This review summarizes the progress of the application of HTS in ocular diseases, intending to explore the pathogenesis of eye diseases and improve their diagnosis.

Indexed as

biomarkershigh-throughput sequencingmicroRNAnext-generation sequencingocular disease

Identifiers

PMID35743555
PMCPMC9225376
OpenAlexW4283022459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.